

STN Columbus

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	26	JUN 06	KOREPAT updated with 41,000 documents
NEWS	27	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	28	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	29	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS	30	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	31	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS	32	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS	33	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS EXPRESS		JUNE 27 08	CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 16:42:46 ON 30 JUN 2008

FILE 'REGISTRY' ENTERED AT 16:42:58 ON 30 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 JUN 2008 HIGHEST RN 1031692-95-1
DICTIONARY FILE UPDATES: 29 JUN 2008 HIGHEST RN 1031692-95-1

New CAS Information Use Policies. enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stinger/stndoc/properties.html>

=> e myriocin/cn

E1	1	MYRININ/CN
E2	1	MYRIOCARPIN/CN
E3	1	--> MYRIOCIN/CN
E4	1	MYRIOCIN, ANHYDRO-/CN
E5	1	MYRIOGYNYC ACID/CN
E6	1	MYRIOGYNYN/CN
E7	1	MYRIONEURINOL/CN
E8	1	MYRIONINE/CN
E9	1	MYRIONINE HYDRIODIDE/CN
E10	1	MYRIONINE HYDROCHLORIDE/CN
E11	1	MYRIOPHYLLOSIDE/CN
E12	1	MYRIOPHYLLOSIDE A/CN

=> s e3
L1 1 MYRIOCIN/CN


$\Rightarrow d$

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN
RN 35891-70-4 REGISTRY
ED Entered STN: 16 Nov 1984
CN 6-Eicosenoic acid, 2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxo-,
(2S,3R,4R,6E)- (CA INDEX NAME)

OTHER CA INDEX NAMES:
CN 6-Eicosenoic acid, 2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxo-,
[2S-(2R*,3S*,4S*,6E)]-
OTHER NAMES:
CN (+)-Myriocin
CN (2S,3R,4R)-(E)-2-Amino-3,4-dihydroxy-2-hydroxymethyl-14-oxoeicos-6-enoic
acid
CN ISP-I
CN **Myriocin**
CN Thermozymocidin
FS STEREOSEARCH

DR 36564-60-0, 37836-36-5
 MF C21 H39 N O6
 LC STN Files: AGRICOLA, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS,
 CASREACT, CHEMCATS, CSCHEM, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB,
 IMSDRUGNEWS, IMSRESEARCH, MEDLINE, NAPRALERT, PHAR, PROMT, PROUSDDR,
 RTECS*, TOXCENTER, USPAT2, USPATFULL
 (*File contains numerically searchable property data)

Absolute stereochemistry.
 Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

126 REFERENCES IN FILE CA (1907 TO DATE)
 5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 127 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file drugu		SINCE FILE	TOTAL
COST IN U.S. DOLLARS		ENTRY	SESSION
FULL ESTIMATED COST		8.07	8.28

FILE 'DRUGU' ENTERED AT 16:44:06 ON 30 JUN 2008
 COPYRIGHT (C) 2008 THOMSON REUTERS

FILE LAST UPDATED: 30 JUN 2008 <20080630/UP>
 >>> DERWENT DRUG FILE (SUBSCRIBER) <<<

>>> FILE COVERS 1983 TO DATE <<<
 >>> THESAURUS AVAILABLE IN /CT <<<

>>> PLEASE NOTE THAT THE COPYRIGHT NOTIFICATION HAS CHANGED <<<

=> s 11
 L2 3 L1

=> d 1-3

L2 ANSWER 1 OF 3 DRUGU COPYRIGHT 2008 THOMSON REUTERS on STN
Full Text
 AN 1993-19972 DRUGU C
 TI A Formal Synthesis of a Novel Immunosuppressant ISP-1: Stereocontrolled Pd(0) Catalyzed cis-Hydroxyamination of Carbohydrate Derived Vinyl Epoxide.
 AU Rao A V R; Gurjar M K; Devi T R; Kumar K R
 LO Hyderabad, India
 SO Tetrahedron Lett. (34, No. 10, 1653-56, 1993) 1 Fig. 14 Ref.
 CODEN: TELEAY ISSN: 0040-4039
 AV Indian Institute of Chemical Technology, Hyderabad 500 007, India.
 LA English
 DT Journal
 FA AB; LA; CT; MPC
 FS Literature

L2 ANSWER 2 OF 3 DRUGU COPYRIGHT 2008 THOMSON REUTERS on STN
 AN 26347 DRUGU
 FS Registry
 DDRN MYRIOCIN
 DDN MYRIOCIN
 RN 35891-70-4
 CT ANTIBIOTICS; IMMUNOSUPPRESSIVES

SS KETOACID; AMINOACID; HYDROXYACID; AMINOALCOHOL; POLYALCOHOL; OLEFIN
L2 ANSWER 3 OF 3 DRUGU COPYRIGHT 2008 THOMSON REUTERS on STN
AN 23353 DRUGU
FS Registry
DDRN THERMOZYM
DDN THERMOZYMOCIDIN
RN 35891-70-4
CT ANTIBIOTICS
SS KETOACID; AMINOACID; HYDROXYACID; AMINOALCOHOL; POLYALCOHOL OLEFIN
MPC 11& *G; 114 *G; 115 *G; 118 *G; 12& *G; 124 *G; 126 *G; 127 *G; 13& *G;
130 *G; 131 *G; 133 *G; 14- *G; 153 *G; 182 *G; 190 *G; 231 *G; 232 *G;
237 *G

=> file medline
COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE ENTRY 3.81	TOTAL SESSION 12.09
-----------------------------	---------------------------

FILE 'MEDLINE' ENTERED AT 16:44:36 ON 30 JUN 2008

FILE LAST UPDATED: 28 Jun 2008 (20080628/UP). FILE COVERS 1949 TO DATE.

MEDLINE has been updated with the National Library of Medicine's revised 2008 MeSH terms. See [HELP RLOAD](#) for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

See HELP RANGE before carrying out any RANGE search.

=> s 11
L3 79 L1

=> s myriocin
L4 102 MYRIOCIN

=> s 13 or 14
L5 132 L3 OR L4

```
=> s (serine palmitoyltransferase inhibit? or spt?)  
      105330 SERINE  
      2264 PALMITOYLTRANSFERASE  
      1430174 INHIBIT?  
          12 SERINE PALMITOYLTRANSFERASE INHIBIT?  
              (SERINE(W)PALMITOYLTRANSFERASE(W) INHIBIT?)  
      2970 SPT?  
L6      2979 (SERINE PALMITOYLTRANSFERASE INHIBIT? OR SPT)
```

=> s atherosclerosis
L7 56663 ATHEROSCLEROSIS

=> s 15 and 17
1.8 6 1.5 AND 1.7

=> s 16 and 17
1.9 5 1.6 AND 1.7

=> d 18 1-6

L8 ANSWER 1 OF 6 MEDLINE on SIN
Full Text

Full Text

AN 2008078932 MEDLINE
DN PubMed ID: 17963772

DN PubMed ID: 17983772
TI Ceramide: a common

II Ceramide: a common pathway for atherosclerosis.
All Bismuth Jean; Lin Peter; Yao Qizhi; Chen Changyi

AS BISHOP Sean, LIN Peter, YAO Qizhi, CHEN Changyu
GS Molecular Surgeon Research Center, Division of

CS Molecular Surgeon Research Center, Division of Vascular Surgery and Endovascular Therapy. Michael E. DeBakey Department of Surgery, Baylor

Endovascular therapy, Michael E. Debakey Department of Surgery, Baylor College of Medicine, Houston, TX, United States

NC COLLEGE OF MEDICINE, HOUSTON,
AT003094 (UNITED STATES NCCAM)

DE15543 (United States NIDCR)

EB-002436 (United States NIBIB)
HL076345 (United States NHLBI)
HL083471 (United States NHLBI)
HL65916 (United States NHLBI)
HL72716 (United States NHLBI)
SO Atherosclerosis, (2008 Feb) Vol. 196, No. 2, pp. 497-504. Electronic
Publication: 2007-10-25. Ref: 92
Journal code: 0242543. E-ISSN: 1879-1484.
CY Ireland
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, N.I.H., EXTRAMURAL)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200803
ED Entered STN: 2 Feb 2008
Last Updated on STN: 25 Mar 2008
Entered Medline: 24 Mar 2008

L8 ANSWER 2 OF 6 MEDLINE on STN

Full Text
AN 2008045038 MEDLINE
DN PubMed ID: 17978313
TI **Myriocin** slows the progression of established atherosclerotic lesions in apolipoprotein E gene knockout mice.
AU Glaros Elias N; Kim Woojin S; Quinn Carmel M; Jessup Wendy; Rye Kerry-Anne; Garner Brett
CS Prince of Wales Medical Research Institute, Randwick, NSW 2031, Australia.
SO Journal of lipid research, (2008 Feb) Vol. 49, No. 2, pp. 324-31.
Electronic Publication: 2007-10-31.
Journal code: 0376606. ISSN: 0022-2275.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200804
ED Entered STN: 18 Jan 2008
Last Updated on STN: 23 Apr 2008
Entered Medline: 22 Apr 2008

L8 ANSWER 3 OF 6 MEDLINE on STN

Full Text
AN 2007183937 MEDLINE
DN PubMed ID: 17239824
TI Inhibition of **atherosclerosis** by the serine palmitoyl transferase inhibitor **myriocin** is associated with reduced plasma glycosphingolipid concentration.
AU Glaros Elias N; Kim Woojin S; Wu Benjamin J; Suarna Cacang; Quinn Carmel M; Rye Kerry-Anne; Stocker Roland; Jessup Wendy; Garner Brett
CS Prince of Wales Medical Research Institute, Randwick, NSW 2031, Australia.
SO Biochemical pharmacology, (2007 May 1) Vol. 73, No. 9, pp. 1340-6.
Electronic Publication: 2006-12-27.
Journal code: 0101032. ISSN: 0006-2952.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200705
ED Entered STN: 28 Mar 2007
Last Updated on STN: 18 May 2007
Entered Medline: 17 May 2007

L8 ANSWER 4 OF 6 MEDLINE on STN

Full Text
AN 2006633731 MEDLINE
DN PubMed ID: 16458317
TI Modulation of lipoprotein metabolism by inhibition of sphingomyelin synthesis in ApoE knockout mice.
AU Park Tae-Sik; Panek Robert L; Rekhter Mark D; Mueller Sandra Bak; Rosebury Wendy S; Robertson Andrew; Hanselman Jeffrey C; Kindt Erick; Homan Reynold; Karathanasis Sotirios K

CS Cardiovascular Pharmacology, Pfizer Global Research and Development, Ann Arbor, MI 48105, USA.. tp2156@columbia.edu
SO Atherosclerosis, (2006 Dec) Vol. 189, No. 2, pp. 264-72. Electronic Publication: 2006-02-02.
Journal code: 0242543. ISSN: 0021-9150.
CY Ireland
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200701
ED Entered STN: 31 Oct 2006
Last Updated on STN: 31 Jan 2007
Entered Medline: 30 Jan 2007

L8 ANSWER 5 OF 6 MEDLINE on STN

Full Text

AN 2005132765 MEDLINE
DN PubMed ID: 15590644
TI Effect of **myriocin** on plasma sphingolipid metabolism and **atherosclerosis** in apoE-deficient mice.
AU Hojjati Mohammad Reza; Li Zhiqiang; Zhou Hongwen; Tang Songshan; Huan Chongmin; Ooi Everlyn; Lu Shendi; Jiang Xian-Cheng
CS Department of Anatomy and Cell Biology, State University of New York Downstate Medical Center, 450 Clarkson Ave., Brooklyn, New York 11203, USA.
NC HL-64735 (United States NHLBI)
HL-69817 (United States NHLBI)
SO The Journal of biological chemistry, (2005 Mar 18) Vol. 280, No. 11, pp. 10284-9. Electronic Publication: 2004-12-06.
Journal code: 2985121R. ISSN: 0021-9258.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
LA English
FS Priority Journals
EM 200504
ED Entered STN: 15 Mar 2005
Last Updated on STN: 26 Apr 2005
Entered Medline: 25 Apr 2005

L8 ANSWER 6 OF 6 MEDLINE on STN

Full Text

AN 2004595840 MEDLINE
DN PubMed ID: 15569847
TI Sphingolipids and **atherosclerosis**: a mechanistic connection? A therapeutic opportunity?.
AU Tabas Ira
NC R01 HL56984 (United States NHLBI)
SO Circulation, (2004 Nov 30) Vol. 110, No. 22, pp. 3400-1.
Journal code: 0147763. E-ISSN: 1524-4539.
CY United States
DT Commentary
(COMPARATIVE STUDY)
Editorial
(RESEARCH SUPPORT, N.I.H., EXTRAMURAL)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 200506
ED Entered STN: 1 Dec 2004
Last Updated on STN: 14 Jun 2005
Entered Medline: 13 Jun 2005

=> d his

(FILE 'HOME' ENTERED AT 16:42:46 ON 30 JUN 2008)

FILE 'REGISTRY' ENTERED AT 16:42:58 ON 30 JUN 2008
E MYRIOCIN/CN

L1 1 S E3

FILE 'DRUGU' ENTERED AT 16:44:06 ON 30 JUN 2008

L2 3 S L1

FILE 'MEDLINE' ENTERED AT 16:44:36 ON 30 JUN 2008

L3 79 S L1
L4 102 S MYRIOCIN
L5 132 S L3 OR L4
L6 2979 S (SERINE PALMITOYLTRANSFERASE INHIBIT? OR SPT?)
L7 56663 S ATHEROSCLEROSIS
L8 6 S L5 AND L7
L9 5 S L6 AND L7

=> d 19 1-5

L9 ANSWER 1 OF 5 MEDLINE on STN

Full Text

AN 2007476556 MEDLINE
DN PubMed ID: 17602566
TI Inhibition of reactive nitrogen species in vitro and ex vivo by trypsin inhibitor from sweet potato 'Tainong 57' storage roots.
AU Huang Guan-Jhong; Sheu Ming-Jyh; Chen Hsien-Jung; Chang Yuan-Shiun; Lin Yaw-Huei
CS Institute of Chinese Pharmaceutical Sciences and Department of Physiology, School of Medicine, China Medical University, Taichung 404, Taiwan..
gjhuang@mail.cmu.edu.tw
SO Journal of agricultural and food chemistry, (2007 Jul 25) Vol. 55, No. 15, pp. 6000-6. Electronic Publication: 2007-06-28.
Journal code: 0374755. ISSN: 0021-8561.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200710
ED Entered STN: 16 Aug 2007
Last Updated on STN: 10 Oct 2007
Entered Medline: 9 Oct 2007

L9 ANSWER 2 OF 5 MEDLINE on STN

Full Text

AN 2007183937 MEDLINE
DN PubMed ID: 17239824
TI Inhibition of **atherosclerosis** by the serine palmitoyl transferase inhibitor myriocin is associated with reduced plasma glycosphingolipid concentration.
AU Glaros Elias N; Kim Woojin S; Wu Benjamin J; Suarna Cacang; Quinn Carmel M; Rye Kerry-Anne; Stocker Roland; Jessup Wendy; Garner Brett
CS Prince of Wales Medical Research Institute, Randwick, NSW 2031, Australia.
SO Biochemical pharmacology, (2007 May 1) Vol. 73, No. 9, pp. 1340-6.
Electronic Publication: 2006-12-27.
Journal code: 0101032. ISSN: 0006-2952.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200705
ED Entered STN: 28 Mar 2007
Last Updated on STN: 18 May 2007
Entered Medline: 17 May 2007

L9 ANSWER 3 OF 5 MEDLINE on STN

Full Text

AN 2005578244 MEDLINE
DN PubMed ID: 16216550
TI Serine palmitoyl-CoA transferase (**SPT**) deficiency and sphingolipid levels in mice.
AU Hojjati Mohammad Reza; Li Zhiqiang; Jiang Xian-Cheng
CS Department of Anatomy and Cell Biology, SUNY Downstate Medical Center, 450 Clarkson Ave. Box 5, Brooklyn, NY 11203, USA.
NC HL-64735 (United States NHLBI)
HL-69817 (United States NHLBI)
SO Biochimica et biophysica acta, (2005 Oct 15) Vol. 1737, No. 1, pp. 44-51.

Electronic Publication: 2005-08-24.
 Journal code: 0217513. ISSN: 0006-3002.
 CY Netherlands
 DT Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, N.I.H., EXTRAMURAL)
 LA English
 FS Priority Journals
 EM 200512
 ED Entered STN: 1 Nov 2005
 Last Updated on STN: 22 Dec 2005
 Entered Medline: 20 Dec 2005

L9 ANSWER 4 OF 5 MEDLINE on STN
Full Text
 AN 2005132765 MEDLINE
 DN PubMed ID: 15590644
 TI Effect of myriocin on plasma sphingolipid metabolism and **atherosclerosis** in apoE-deficient mice.
 AU Hojjati Mohammad Reza; Li Zhiqiang; Zhou Hongwen; Tang Songshan; Huan Chongmin; Ooi Evelyn; Lu Shendi; Jiang Xian-Cheng
 CS Department of Anatomy and Cell Biology, State University of New York Downstate Medical Center, 450 Clarkson Ave., Brooklyn, New York 11203, USA.
 NC HL-64735 (United States NHLBI)
 HL-69817 (United States NHLBI)
 SO The Journal of biological chemistry, (2005 Mar 18) Vol. 280, No. 11, pp. 10284-9. Electronic Publication: 2004-12-06.
 Journal code: 2985121R. ISSN: 0021-9258.

CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
 LA English
 FS Priority Journals
 EM 200504
 ED Entered STN: 15 Mar 2005
 Last Updated on STN: 26 Apr 2005
 Entered Medline: 25 Apr 2005

L9 ANSWER 5 OF 5 MEDLINE on STN
Full Text
 AN 2004595840 MEDLINE
 DN PubMed ID: 15569847
 TI Sphingolipids and **atherosclerosis**: a mechanistic connection? A therapeutic opportunity?.
 AU Tabas Ira
 NC R01 HL56984 (United States NHLBI)
 SO Circulation, (2004 Nov 30) Vol. 110, No. 22, pp. 3400-1.
 Journal code: 0147763. E-ISSN: 1524-4539.
 CY United States
 DT Commentary
 (COMPARATIVE STUDY)
 Editorial
 (RESEARCH SUPPORT, N.I.H., EXTRAMURAL)
 (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 200506
 ED Entered STN: 1 Dec 2004
 Last Updated on STN: 14 Jun 2005
 Entered Medline: 13 Jun 2005

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	3.84	15.93

FILE 'CA' ENTERED AT 16:47:26 ON 30 JUN 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Jun 2008 VOL 149 ISS 1
FILE LAST UPDATED: 26 Jun 2008 (20080626/ED)

CA now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 16:42:46 ON 30 JUN 2008)

FILE 'REGISTRY' ENTERED AT 16:42:58 ON 30 JUN 2008
E MYRIOCIN/CN

L1 1 S E3

FILE 'DRUGU' ENTERED AT 16:44:06 ON 30 JUN 2008
L2 3 S L1

FILE 'MEDLINE' ENTERED AT 16:44:36 ON 30 JUN 2008

L3 79 S L1
L4 102 S MYRIOCIN
L5 132 S L3 OR L4
L6 2979 S (SERINE PALMITOYLTRANSFERASE INHIBIT? OR SPT?)
L7 56663 S ATHEROSCLEROSIS
L8 6 S L5 AND L7
L9 5 S L6 AND L7

FILE 'CA' ENTERED AT 16:47:26 ON 30 JUN 2008

=> s l1
L10 126 L1

=> s myriocin/ab,bi
149 MYRIOCIN/AB
183 MYRIOCIN/BI
L11 183 MYRIOCIN/AB,BI

=> s l10 or l11
L12 208 L10 OR L11

=> s (serine palmitoyltransferase inhibit? or spt?)/ab,bi
85207 SERINE/AB
1726 PALMITOYLTRANSFERASE/AB
1685580 INHIBIT?/AB
12 SERINE PALMITOYLTRANSFERASE INHIBIT?/AB
((SERINE(W)PALMITOYLTRANSFERASE(W)INHIBIT?)/AB)
118540 SERINE/BI
2218 PALMITOYLTRANSFERASE/BI
1989932 INHIBIT?/BI
40 SERINE PALMITOYLTRANSFERASE INHIBIT?/BI
((SERINE(W)PALMITOYLTRANSFERASE(W)INHIBIT?)/BI)
2239 SPT?/AB
2657 SPT?/BI
L13 2680 (SERINE PALMITOYLTRANSFERASE INHIBIT? OR SPT?)/AB,BI

=> s atherosclerosis/ab,bi

35883 ATHEROSCLEROSIS/AB
58627 ATHEROSCLEROSIS/BI
L14 58627 ATHEROSCLEROSIS/AB, BI

=> s 112 and 114
L15 9 L12 AND L14

=> s 113 and 114
L16 14 L13 AND L14

=> d 115 1-9

L15 ANSWER 1 OF 9 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 148:557962 CA
TI SPTLC1 Binds ABCA1 To Negatively Regulate Trafficking and Cholesterol Efflux Activity of the Transporter
AU Tamehiro, Norimasa; Zhou, Suiping; Okuhira, Keiichiro; Benita, Yair; Brown, Cari E.; Zhuang, Debbie Z.; Latz, Eicke; Hornemann, Thorsten; von Eckardstein, Arnold; Xavier, Ramnik J.; Freeman, Mason W.; Fitzgerald, Michael L.
CS Lipid Metabolism Unit and Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA, 02114, USA
SO Biochemistry (2008), 47(23), 6138-6147
CODEN: BICHAW; ISSN: 0006-2960
PB American Chemical Society
DT Journal
LA English
RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 9 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 148:235953 CA
TI **Myriocin** slows the progression of established atherosclerotic lesions in apolipoprotein E gene knockout mice
AU Glaros, Elias N.; Kim, Woojin S.; Quinn, Carmel M.; Jessup, Wendy; Rye, Kerry-Anne; Garner, Brett
CS Prince of Wales Medical Research Institute, Randwick NSW, 2031, Australia
SO Journal of Lipid Research (2008), 49(2), 324-331
CODEN: JLPRAW; ISSN: 0022-2275
PB American Society for Biochemistry and Molecular Biology, Inc.
DT Journal
LA English
RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 3 OF 9 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 146:492927 CA
TI Inhibition of **atherosclerosis** by the serine palmitoyl transferase inhibitor **myriocin** is associated with reduced plasma glycosphingolipid concentration
AU Glaros, Elias N.; Kim, Woojin S.; Wu, Benjamin J.; Suarna, Cacang; Quinn, Carmel M.; Rye, Kerry-Anne; Stocker, Roland; Jessup, Wendy; Garner, Brett
CS Prince of Wales Medical Research Institute, Randwick, 2031, Australia
SO Biochemical Pharmacology (2007), 73(9), 1340-1346
CODEN: BCPCA6; ISSN: 0006-2952
PB Elsevier B.V.
DT Journal
LA English
RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 4 OF 9 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 146:19933 CA
TI Modulation of lipoprotein metabolism by inhibition of sphingomyelin synthesis in ApoE knockout mice
AU Park, Tae-Sik; Panek, Robert L.; Rekhter, Mark D.; Mueller, Sandra Bak; Rosebury, Wendy S.; Robertson, Andrew; Hanselman, Jeffrey C.; Kindt, Erick; Homan, Reynold; Karathanasis, Sotirios K.

CS Cardiovascular Pharmacology, Pfizer Global Research and Development, Ann Arbor, MI, 48105, USA
 SO Atherosclerosis (Amsterdam, Netherlands) (2006), 189(2), 264-272
 CODEN: ATHSBL; ISSN: 0021-9150
 PB Elsevier B.V.
 DT Journal
 LA English

RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 5 OF 9 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 144:390641 CA
 TI Preparation of **myriocin** analogs for use in pharmaceutical compositions for treating insulin resistance and cardiomyopathy
 IN Nestor, John
 PA Therapei Pharmaceuticals, Inc., USA
 SO U.S. Pat. Appl. Publ., 23 pp.
 CODEN: USXXCO

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20060079542	A1	20060413	US 2005-248491	20051012
	US 7189748	B2	20070313		
	AU 2005295080	A1	20060420	AU 2005-295080	20051012
	CA 2583947	A1	20060420	CA 2005-2583947	20051012
	WO 2006042278	A1	20060420	WO 2005-US36702	20051012
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 1799217	A1	20070627	EP 2005-809923	20051012
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	CN 101060845	A	20071024	CN 2005-80039238	20051012
	JP 2008515987	T	20080515	JP 2007-536845	20051012
	US 20070135450	A1	20070614	US 2006-618120	20061229
	IN 2007DN02662	A	20070803	IN 2007-DN2662	20070410
	MX 200704262	A	20080304	MX 2007-4262	20070411
	KR 2007085250	A	20070827	KR 2007-708297	20070412
PRAI	US 2004-617911P	P	20041012		
	US 2005-664835P	P	20050323		
	US 2005-664919P	P	20050323		
	US 2005-693463P	P	20050623		
	US 2005-248491	A1	20051012		
	WO 2005-US36702	W	20051012		

OS CASREACT 144:390641; MARPAT 144:390641

RE.CNT 88 THERE ARE 88 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 6 OF 9 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 143:339656 CA
 TI Use of a serine palmitoyltransferase (spt) inhibitor to treat **atherosclerosis** and dyslipidemia
 IN Homan, Reynold; Karathanasis, Sotirios Konstantinou; Panek, Robert Lee; Park, Tae-Sik; Rekhter, Mark David
 PA Warner-Lambert Company LLC, USA
 SO PCT Int. Appl., 53 pp.
 CODEN: PIXXD2
 DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005092325	A1	20051006	WO 2005-IB733	20050321
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA	2560920	A1	20051006	CA 2005-2560920	20050321
EP	1732538	A1	20061220	EP 2005-708781	20050321
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
BR	2005007998	A	20070731	BR 2005-7998	20050321
JP	2007530528	T	20071101	JP 2007-504503	20050321
MX	2006PA11060	A	20061116	MX 2006-PA11060	20060926
US	20080027088	A1	20080131	US 2007-594348	20070815
PRAI	US 2004-557021P	P	20040326		
	WO 2005-IB733	W	20050321		

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 7 OF 9 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 142:385619 CA
TI Effect of **Myriocin** on Plasma Sphingolipid Metabolism and **Atherosclerosis** in apoE-deficient Mice
AU Hojjati, Mohammad Reza; Li, Zhiqiang; Zhou, Hongwen; Tang, Songshan; Huan, Chongmin; Ooi, Evelyn; Lu, Shendi; Jiang, Xian-Cheng
CS Department of Anatomy and Cell Biology, State University of New York Downstate Medical Center, Brooklyn, NY, 11203, USA
SO Journal of Biological Chemistry (2005), 280(11), 10284-10289
CODEN: JBCHA3; ISSN: 0021-9258
PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English

RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 8 OF 9 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 142:111534 CA
TI Inhibition of Sphingomyelin Synthesis Reduces Atherogenesis in Apolipoprotein E-Knockout Mice
AU Park, Tae-Sik; Panek, Robert L.; Mueller, Sandra Bak; Hanselman, Jeffrey C.; Rosebury, Wendy S.; Robertson, Andrew W.; Kindt, Erick K.; Homan, Reynold; Karathanasis, Sotirios K.; Rekhter, Mark D.
CS Cardiovascular Pharmacology, Pfizer Global Research and Development, Ann Arbor, MI, USA
SO Circulation (2004), 110(22), 3465-3471
CODEN: CIRCAZ; ISSN: 0009-7322
PB Lippincott Williams & Wilkins
DT Journal
LA English

RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 9 OF 9 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 135:341174 CA
TI Detection and treatment of **atherosclerosis** based on plasma sphingomyelin concentration
IN Tall, Alan R.; Jiang, Xian-Cheng
PA Trustees of Columbia University in the City of New York, USA
SO PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001080903	A1	20011101	WO 2001-US12706	20010419
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2000-551947	A	20000419		
OS	MARPAT	135:341174			

=> d his

(FILE 'HOME' ENTERED AT 16:42:46 ON 30 JUN 2008)

FILE 'REGISTRY' ENTERED AT 16:42:58 ON 30 JUN 2008
E MYRIOCIN/CN

L1 1 S E3

FILE 'DRUGU' ENTERED AT 16:44:06 ON 30 JUN 2008
L2 3 S L1

FILE 'MEDLINE' ENTERED AT 16:44:36 ON 30 JUN 2008
L3 79 S L1
L4 102 S MYRIOCIN
L5 132 S L3 OR L4
L6 2979 S (SERINE PALMITOYLTRANSFERASE INHIBIT? OR SPT?)
L7 56663 S ATHEROSCLEROSIS
L8 6 S L5 AND L7
L9 5 S L6 AND L7

FILE 'CA' ENTERED AT 16:47:26 ON 30 JUN 2008
L10 126 S L1
L11 183 S MYRIOCIN/AB,BI
L12 208 S L10 OR L11
L13 2680 S (SERINE PALMITOYLTRANSFERASE INHIBIT? OR SPT?) /AB,BI
L14 58627 S ATHEROSCLEROSIS/AB,BI
L15 9 S L12 AND L14
L16 14 S L13 AND L14

=> d 116 1-14

L16 ANSWER 1 OF 14 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 148:557962 CA

TI SPTLC1 Binds ABCA1 To Negatively Regulate Trafficking and Cholesterol Efflux Activity of the Transporter
AU Tamehiro, Norimasa; Zhou, Suiping; Okuhira, Keiichiro; Benita, Yair; Brown, Cari E.; Zhuang, Debbie Z.; Latz, Eicke; Hornemann, Thorsten; von Eckardstein, Arnold; Xavier, Ramnik J.; Freeman, Mason W.; Fitzgerald, Michael L.
CS Lipid Metabolism Unit and Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA, 02114, USA

SO Biochemistry (2008), 47(23), 6138-6147
CODEN: BICHAW; ISSN: 0006-2960

PB American Chemical Society

DT Journal

LA English

RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 2 OF 14 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 148:441026 CA
 TI Preparation of cyclic and aliphatic compounds as serine palmitoyltransferase modulators for treating metabolic syndrome and inflammation
 IN Nestor, John
 PA Forbes Medi-Tech (Research), Inc., USA
 SO PCT Int. Appl., 67pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008046071	A2	20080417	WO 2007-US81303	20071012
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 20080139455	A1	20080612	US 2007-871720	20071012
PRAI	US 2006-829277P	P	20061012		
OS	MARPAT 148:441026				

L16 ANSWER 3 OF 14 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 148:331424 CA
 TI Preparation of benzene derivatives as serine palmitoyl transferase inhibitors
 IN Nestor, John
 PA Forbes Medi-Tech (Research), Inc., USA
 SO PCT Int. Appl., 64pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008031032	A2	20080313	WO 2007-US77884	20070907
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 20080096799	A1	20080424	US 2007-851935	20070907
PRAI	US 2006-824897P	P	20060907		
OS	MARPAT 148:331424				

L16 ANSWER 4 OF 14 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 147:539679 CA
 TI Alleles and polymorphisms associated with type 2 diabetes mellitus and obesity and their diagnostic use
 IN Salonen, Jukka T.; Hypponen, Jelena; Kaikonen, Jari; Pirskanen, Mia; Uimari, Pekka; Aalto, Juha-Matti
 PA Oy Jurilab Ltd., Finland
 SO PCT Int. Appl., 456pp.
 CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007128884	A1	20071115	WO 2007-FI50266	20070509
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 20070292412	A1	20071220	US 2007-798002	20070509
PRAI	US 2006-798706P	P	20060509		
	US 2006-798774P	P	20060509		
	US 2006-805522P	P	20060622		
	US 2006-819015P	P	20060707		
	US 2006-827306P	P	20060928		
	US 2006-863438P	P	20061030		
	US 2006-864681P	P	20061107		

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 5 OF 14 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 147:79006 CA
TI Inhibition of reactive nitrogen species in vitro and ex vivo by trypsin inhibitor from sweet potato 'Tainong 57' storage roots
AU Huang, Guan-Jhong; Sheu, Ming-Jyh; Chen, Hsien-Jung; Chang, Yuan-Shiun; Lin, Yaw-Huei
CS Institute of Chinese Pharmaceutical Sciences and Department of Physiology, School of Medicine, China Medical University, Taichung, 404, Taiwan
SO Journal of Agricultural and Food Chemistry (2007), 55(15), 6000-6006
CODEN: JAFCAU; ISSN: 0021-8561
PB American Chemical Society
DT Journal
LA English

RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 6 OF 14 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 146:492927 CA
TI Inhibition of **atherosclerosis** by the serine palmitoyl transferase inhibitor myriocin is associated with reduced plasma glycosphingolipid concentration
AU Glaros, Elias N.; Kim, Woojin S.; Wu, Benjamin J.; Suarna, Cacang; Quinn, Carmel M.; Rye, Kerry-Anne; Stocker, Roland; Jessup, Wendy; Garner, Brett
CS Prince of Wales Medical Research Institute, Randwick, 2031, Australia
SO Biochemical Pharmacology (2007), 73(9), 1340-1346
CODEN: BCPCA6; ISSN: 0006-2952
PB Elsevier B.V.
DT Journal
LA English

RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 7 OF 14 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 146:19933 CA
TI Modulation of lipoprotein metabolism by inhibition of sphingomyelin synthesis in ApoE knockout mice
AU Park, Tae-Sik; Panek, Robert L.; Rekhter, Mark D.; Mueller, Sandra Bak; Rosebury, Wendy S.; Robertson, Andrew; Hanselman, Jeffrey C.; Kindt, Erick; Homan, Reynold; Karathanasis, Sotirios K.
CS Cardiovascular Pharmacology, Pfizer Global Research and Development, Ann Arbor, MI, 48105, USA

SO Atherosclerosis (Amsterdam, Netherlands) (2006), 189(2), 264-272

CODEN: ATHSBL; ISSN: 0021-9150

PB Elsevier B.V.

DT Journal

LA English

RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 8 OF 14 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 144:49621 CA

TI Serine palmitoyl-CoA transferase (**SPT**) deficiency and sphingolipid levels in mice

AU Hojjati, Mohammad Reza; Li, Zhiqiang; Jiang, Xian-Cheng

CS Department of Anatomy and Cell Biology, SUNY Downstate Medical Center, Brooklyn, NY, 11203, USA

SO Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids (2005), 1737(1), 44-51

CODEN: BBMLFG; ISSN: 1388-1981

PB Elsevier B.V.

DT Journal

LA English

RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 9 OF 14 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 143:339656 CA

TI Use of a serine palmitoyltransferase (**spt**) inhibitor to treat **atherosclerosis** and dyslipidemia

IN Homan, Reynold; Karathanasis, Sotirios Konstantinou; Panek, Robert Lee; Park, Tae-Sik; Rekhter, Mark David

PA Warner-Lambert Company LLC, USA

SO PCT Int. Appl., 53 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005092325	A1	20051006	WO 2005-IB733	20050321
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2560920	A1	20051006	CA 2005-2560920	20050321
	EP 1732538	A1	20061220	EP 2005-708781	20050321
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	BR 2005007998	A	20070731	BR 2005-7998	20050321
	JP 2007530528	T	20071101	JP 2007-504503	20050321
	MX 2006PA11060	A	20061116	MX 2006-PA11060	20060926
	US 20080027088	A1	20080131	US 2007-594348	20070815
PRAI	US 2004-557021P	P	20040326		
	WO 2005-IB733	W	20050321		

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 10 OF 14 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 143:272498 CA

TI Gene expression profiles in the diagnosis and treatment of Alzheimer's disease

IN Landfield, Philip W.; Porter, Nada M.; Chen, Kuey Chu; Geddes, James; Blalock, Eric

PA University of Kentucky Research Foundation, USA

SO PCT Int. Appl., 114 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005076939	A2	20050825	WO 2005-US3668	20050209
	WO 2005076939	A3	20060706		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20070082350	A1	20070412	US 2006-501226	20060809
PRAI	US 2004-542281P	P	20040209		
	WO 2005-US3668	A	20050209		

L16 ANSWER 11 OF 14 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 142:385619 CA

TI Effect of Myriocin on Plasma Sphingolipid Metabolism and **Atherosclerosis** in apoE-deficient Mice

AU Hojjati, Mohammad Reza; Li, Zhiqiang; Zhou, Hongwen; Tang, Songshan; Huan, Chongmin; Ooi, Everlyn; Lu, Shendi; Jiang, Xian-Cheng

CS Department of Anatomy and Cell Biology, State University of New York Downstate Medical Center, Brooklyn, NY, 11203, USA

SO Journal of Biological Chemistry (2005), 280(11), 10284-10289
CODEN: JBCHA3; ISSN: 0021-9258

PB American Society for Biochemistry and Molecular Biology

DT Journal

LA English

RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 12 OF 14 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 140:40262 CA

TI Genes expressed in atherosclerotic tissue and their use in diagnosis and pharmacogenetics

IN Nevins, Joseph; West, Mike; Goldschmidt, Pascal

PA Duke University, USA

SO PCT Int. Appl., 408 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003091391	A2	20031106	WO 2002-XB38221	20021112
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2003091391	A2	20031106	WO 2002-US38221	20021112
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 PRAI US 2002-374547P P 20020423
 US 2002-420784P P 20021024
 US 2002-421043P P 20021025
 US 2002-424680P P 20021108
 WO 2002-US38221 A 20021112

L16 ANSWER 13 OF 14 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 137:243916 CA
 TI Method for measuring serine palmitoyltransferase expression in normal and hyperproliferative mammalian tissues and diagnostic and therapeutic applications
 IN Carton, Jill M.; D'Andrea, Michael R.; Uhlinger, David J.
 PA Ortho-McNeil Pharmaceutical, Inc., USA
 SO PCT Int. Appl., 66 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002074924	A2	20020926	WO 2002-US8383	20020319
	WO 2002074924	A3	20030605		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU	2002254286	A1	20021003	AU 2002-254286	20020319
US	20020197654	A1	20021226	US 2002-100861	20020319
EP	1379679	A2	20040114	EP 2002-723511	20020319
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN	1610751	A	20050427	CN 2002-810014	20020319
JP	2005523416	T	20050804	JP 2002-574317	20020319
MX	2003PA08487	A	20050307	MX 2003-PA8487	20030919
PRAI	US 2001-277252P	P	20010320		
	WO 2002-US8383	W	20020319		

L16 ANSWER 14 OF 14 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 130:2669 CA
 TI Endotoxin and cytokines increase hepatic sphingolipid biosynthesis and produce lipoproteins enriched in ceramides and sphingomyelin
 AU Memon, Riaz A.; Holleran, Walter M.; Moser, Arthur H.; Seki, Taisuke; Uchida, Yoshikazu; Fuller, John; Shigenaga, Judy K.; Grunfeld, Carl; Feingold, Kenneth R.
 CS Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
 SO Arteriosclerosis, Thrombosis, and Vascular Biology (1998), 18(8), 1257-1265
 CODEN: ATVBFA; ISSN: 1079-5642
 PB Lippincott Williams & Wilkins
 DT Journal
 LA English
 RE.CNT 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d kwic ab 14

L16 ANSWER 14 OF 14 CA COPYRIGHT 2008 ACS on STN

AB . . . infections. The authors studied the effects of endotoxin

[lipopolysaccharide (LPS)] and cytokines on hepatic sphingolipid synthesis, activity of serine palmitoyltransferase (**SPT**), the first and rate-limiting enzyme in sphingolipid synthesis, and lipoprotein sphingolipid content in Syrian hamsters. Administration of LPS induced a 2-fold increase in hepatic **SPT** activity. The increase in activity first occurred at 16 h, peaked at 24 h, and was sustained for at least 48 h. Low doses of LPS produced maximal increases in **SPT** activity, with half-maximal effect seen at ≈ 0.3 μ g LPS/100 g body wt. LPS increased hepatic **SPT** mRNA levels 2-fold, suggesting that the increase in **SPT** activity was due to an increase in **SPT** mRNA. LPS treatment also produced 75% and 2.5-fold increases in hepatic sphingomyelin and ceramide synthesis, resp. Many of the metabolic effects of LPS are mediated by cytokines. Interleukin 1 (IL-1), but not tumor necrosis factor, increased both **SPT** activity and mRNA levels in the liver of intact animals, whereas both IL-1 and tumor necrosis factor increased **SPT** mRNA levels in HepG2 cells. IL-1 produced a 3-fold increase in **SPT** mRNA in HepG2 cells, and the half-maximal dose was 2 ng/mL. IL-1 also increased the secretion of sphingolipids into the. . .

IT Acute-phase response

Atherosclerosis

Liver

(endotoxin and cytokines increase of hepatic sphingolipid formation and generation of lipoproteins enriched in ceramides and sphingomyelin in relation to atherogenesis)

AB Alterations in triglyceride and cholesterol metab. often accompany inflammatory diseases and infections. The authors studied the effects of endotoxin [lipopolysaccharide (LPS)] and cytokines on hepatic sphingolipid synthesis, activity of serine palmitoyltransferase (**SPT**), the first and rate-limiting enzyme in sphingolipid synthesis, and lipoprotein sphingolipid content in Syrian hamsters. Administration of LPS induced a 2-fold increase in hepatic **SPT** activity. The increase in activity first occurred at 16 h, peaked at 24 h, and was sustained for at least 48 h. Low doses of LPS produced maximal increases in **SPT** activity, with half-maximal effect seen at ≈ 0.3 μ g LPS/100 g body wt. LPS increased hepatic **SPT** mRNA levels 2-fold, suggesting that the increase in **SPT** activity was due to an increase in **SPT** mRNA. LPS treatment also produced 75% and 2.5-fold increases in hepatic sphingomyelin and ceramide synthesis, resp. Many of the metabolic effects of LPS are mediated by cytokines. Interleukin 1 (IL-1), but not tumor necrosis factor, increased both **SPT** activity and mRNA levels in the liver of intact animals, whereas both IL-1 and tumor necrosis factor increased **SPT** mRNA levels in HepG2 cells. IL-1 produced a 3-fold increase in **SPT** mRNA in HepG2 cells, and the half-maximal dose was 2 ng/mL. IL-1 also increased the secretion of sphingolipids into the medium. Anal. of serum lipoprotein fractions demonstrated that very low d. lipoprotein, intermediate d. lipoprotein, and low d. lipoprotein isolated from animals treated with LPS contained higher amts. of ceramide, glucosylceramide, and sphingomyelin. Thus, LPS and cytokines stimulate hepatic sphingolipid synthesis, which results in an altered structure of circulating lipoproteins and may promote atherogenesis.

=> d kwic ab 13

L16 ANSWER 13 OF 14 CA COPYRIGHT 2008 ACS on STN

AB The present invention is directed to a method for comparatively measuring the level of normal and hyperproliferative serine palmitoyltransferase (**SPT**) expression in a mammalian cell and uses thereof. The distribution of the **SPT1** and **SPT2** subunits may serve as a potential marker of cell activity, where high levels of the enzyme may reflect increased metabolic activity or cell proliferation. The assocn. of increased **SPT** expression in pathophysiol. states, such as cancer, inflammation, and vascular injury, make it a provocative therapeutic target. Diagnostic and drug screening applications of the **SPT** assay of the invention are described.

IT Medical goods

(catheters, balloon, coated by drug contg. **serine palmitoyltransferase inhibitor**; method for measuring serine palmitoyltransferase expression in normal and hyperproliferative mammalian tissues and diagnostic and therapeutic applications)

IT Asthma

Atherosclerosis

Carcinoid

Carcinoma
 Inflammation
 Leukemia
 Lymphoma
 Melanoma
 Multiple myeloma
 Neoplasm
 Neuroglia, neoplasm
 Rheumatoid arthritis
 Sarcoma
 (diagnosis and treatment of; method for measuring serine palmitoyltransferase expression in normal and hyperproliferative mammalian tissues and diagnostic and therapeutic applications)
 IT Drugs
 (**serine palmitoyltransferase inhibitor**
 -contg.; method for measuring serine palmitoyltransferase expression in normal and hyperproliferative mammalian tissues and diagnostic and therapeutic applications)
 IT Cytotoxic agents
 (**serine palmitoyltransferase inhibitor**;
 method for measuring serine palmitoyltransferase expression in normal and hyperproliferative mammalian tissues and diagnostic and therapeutic applications)
 IT Medical goods
 (stents, coated by drug contg. **serine palmitoyltransferase inhibitor**; method for measuring serine palmitoyltransferase expression in normal and hyperproliferative mammalian tissues and diagnostic and therapeutic applications)
 AB The present invention is directed to a method for comparatively measuring the level of normal and hyperproliferative serine palmitoyltransferase (**SPT**) expression in a mammalian cell and uses thereof. The distribution of the **SPT1** and **SPT2** subunits may serve as a potential marker of cell activity, where high levels of the enzyme may reflect increased metabolic activity or cell proliferation. The assocn. of increased **SPT** expression in pathophysiolog. states, such as cancer, inflammation, and vascular injury, make it a provocative therapeutic target. Diagnostic and drug screening applications of the **SPT** assay of the invention are described.

=> file uspatall
 COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	57.46	73.39
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.50	-1.50

FILE 'USPATFULL' ENTERED AT 16:51:14 ON 30 JUN 2008
 CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 16:51:14 ON 30 JUN 2008
 CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 16:51:14 ON 30 JUN 2008
 CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> d 11
 YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:n

=> s 11
 L17 13 L1

=> s myriocin
 L18 72 MYRIOCIN

=> s myriocin/clm
 L19 9 MYRIOCIN/CLM

=> s (serine palmitoyltransferase inhibit? or spt?)
 L20 7642 (SERINE PALMITOYLTRANSFERASE INHIBIT? OR SPT?)

```
=> s (serine palmitoyltransferase inhibit? or spt?)/clm
L21      981 (SERINE PALMITOYLTRANSFERASE INHIBIT? OR SPT?)/CLM

=> s atherosclerosis
L22      42005 ATHEROSCLEROSIS

=> s atherosclerosis/clm
L23      7443 ATHEROSCLEROSIS/CLM

=> s 117 or 118
L24      74 L17 OR L18

=> s 122 and 124
L25      18 L22 AND L24

=> s 117 and 119
L26      6 L17 AND L19

=> s 123 and 126
L27      1 L23 AND L26

=> d
```

L27 ANSWER 1 OF 1 USPATFULL on STN

Full Text

AN 2008:30792 USPATFULL
 TI Imidazole-Based Hmg-Coa Reductase Inhibitors
 IN Homan, Reynold, Ann Arbor, MI, UNITED STATES
 Karathanasis, Sotirios K., Carmel, IN, UNITED STATES
 Panek, Robert L., Ann Arbor, MI, UNITED STATES
 Park, Tae-Sik, Ann Arbor, MI, UNITED STATES
 Rekhter, Mark D., Carmel, IN, UNITED STATES
 PA Warner-Lambert Company, LLC (U.S. corporation)
 PI US 20080027088 A1 20080131
 AI US 2005-594348 A1 20050321 (10)
 WO 2005-IB733 20050321
 20070815 PCT 371 date
 PRAI US 2004-557021P 20040326 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1702
 INCL INCLM: 514/275.000
 INCLS: 514/311.000; 514/356.000; 514/415.000; 514/460.000; 514/560.000;
 514/789.000
 NCL NCLM: 514/275.000
 NCLS: 514/311.000; 514/356.000; 514/415.000; 514/460.000; 514/560.000;
 514/789.000
 IC IPCI A61K0031-201 [I,A]; A61K0031-185 [I,C*]; A61K0031-351 [I,A];
 A61K0031-405 [I,A]; A61K0031-403 [I,C*]; A61K0031-455 [I,A];
 A61K0031-47 [I,A]; A61K0031-505 [I,A]; A61P0003-04 [I,A];
 A61P0003-10 [I,A]; A61P0003-00 [I,C*]
 IPCR A61K0031-185 [I,C]; A61K0031-201 [I,A]; A61K0031-21 [I,C*];
 A61K0031-22 [I,A]; A61K0031-345 [I,C*]; A61K0031-345 [I,A];
 A61K0031-351 [I,C]; A61K0031-351 [I,A]; A61K0031-403 [I,C];
 A61K0031-405 [I,A]; A61K0031-455 [I,C]; A61K0031-455 [I,A];
 A61K0031-47 [I,C]; A61K0031-47 [I,A]; A61K0031-505 [I,C];
 A61K0031-505 [I,A]; A61P0003-00 [I,C]; A61P0003-04 [I,A];
 A61P0003-10 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
=> s 120 and 122
L28      373 L20 AND L22
```

```
=> s 121 and 123
L29      6 L21 AND L23
```

=> d 1-6

L29 ANSWER 1 OF 6 USPATFULL on STN
Full Text

AN 2008:160048 USPATFULL
 TI COMPOUNDS AND METHODS OF TREATING METABOLIC SYNDROME AND INFLAMMATION
 IN Nestor, John J., Encinitas, CA, UNITED STATES
 PA Forbes Medi-Tech (Research), Inc., Seattle, WA, UNITED STATES (U.S.
 corporation)
 PI US 20080139455 A1 20080612
 AI US 2007-871720 A1 20071012 (11)
 PRAI US 2006-829277P 20061012 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2844
 INCL INCLM: 514 4
 INCLS: 514/364.000; 514/394.000; 514/256.000; 514/357.000; 514/399.000;
 544/335.000; 546/335.000; 548/131.000; 548/309.700; 548/339.100;
 562/567.000; 560/037.000; 514/538.000; 514/561.000; 514/012.000;
 435/011.000
 NCL NCLM: 514 4
 NCLS: 514/364.000; 514/394.000; 514/256.000; 514/357.000; 514/399.000;
 544/335.000; 546/335.000; 548/131.000; 548/309.700; 548/339.100;
 562/567.000; 560/037.000; 514/538.000; 514/561.000; 514/012.000;
 435/011.000
 IC IPCI A61K0038-28 [I,A]; A61P0003-00 [I,A]; A61K0031-4245 [I,A];
 A61K0031-4184 [I,A]; A61K0031-505 [I,A]; A61K0031-44 [I,A];
 A61K0031-4164 [I,A]; A61K0031-19 [I,A]; A61K0031-185 [I,C*];
 A61P0003-04 [I,A]; A61P0011-00 [I,A]; A61P0003-10 [I,A];
 A61P0029-00 [I,A]; A61P0009-00 [I,A]; A61K0038-22 [I,A];
 A61K0031-215 [I,A]; A61K0031-21 [I,C*]; C07D0239-26 [I,A];
 C07D0239-00 [I,C*]; C07D0213-55 [I,A]; C07D0213-00 [I,C*];
 C07D0271-06 [I,A]; C07D0271-00 [I,C*]; C07D0235-16 [I,A];
 C07D0235-00 [I,C*]; C07D0233-64 [I,A]; C07D0233-00 [I,C*]

L29 ANSWER 2 OF 6 USPATFULL on STN

Full Text

AN 2008:111249 USPATFULL
 TI COMPOUNDS FOR AND METHODS OF TREATING INSULIN RESISTANCE AND
 INFLAMMATION
 IN Nestor, John, Encinitas, CA, UNITED STATES
 PA FORBES MEDI-TECH (RESEARCH), INC., Seattle, WA, UNITED STATES, 98101
 (U.S. corporation)
 PI US 20080096799 A1 20080424
 AI US 2007-851935 A1 20070907 (11)
 PRAI US 2006-824897P 20060907 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2893
 INCL INCLM: 514/003.000
 INCLS: 544/335.000; 514/256.000
 NCL NCLM: 514/003.000
 NCLS: 514/256.000; 544/335.000
 IC IPCI A61K0038-28 [I,A]; A61P0003-10 [I,A]; A61P0003-00 [I,C*];
 C07D0239-02 [I,A]; C07D0239-00 [I,C*]; A61K0031-4965 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L29 ANSWER 3 OF 6 USPATFULL on STN

Full Text

AN 2008:30792 USPATFULL
 TI Imidazole-Based Hmg-Coa Reductase Inhibitors
 IN Homan, Reynold, Ann Arbor, MI, UNITED STATES
 Karathanasis, Sotirios K., Carmel, IN, UNITED STATES
 Panek, Robert L., Ann Arbor, MI, UNITED STATES
 Park, Tae-Sik, Ann Arbor, MI, UNITED STATES
 Rekhter, Mark D., Carmel, IN, UNITED STATES
 PA Warner-Lambert Company, LLC (U.S. corporation)
 PI US 20080027088 A1 20080131
 AI US 2005-594348 A1 20050321 (10)
 WO 2005-IB733
 20050321
 20070815 PCT 371 date
 PRAI US 2004-557021P 20040326 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1702
 INCL INCLM: 514/275.000

INCLS: 514/311.000; 514/356.000; 514/415.000; 514/460.000; 514/560.000;
514/789.000

NCL NCLM: 514/275.000

NCLS: 514/311.000; 514/356.000; 514/415.000; 514/460.000; 514/560.000;
514/789.000

IC IPCI A61K0031-201 [I,A]; A61K0031-185 [I,C*]; A61K0031-351 [I,A];
A61K0031-405 [I,A]; A61K0031-403 [I,C*]; A61K0031-455 [I,A];
A61K0031-47 [I,A]; A61K0031-505 [I,A]; A61P0003-04 [I,A];
A61P0003-10 [I,A]; A61P0003-00 [I,C*]

IPCR A61K0031-185 [I,C]; A61K0031-201 [I,A]; A61K0031-21 [I,C*];
A61K0031-22 [I,A]; A61K0031-345 [I,C*]; A61K0031-345 [I,A];
A61K0031-351 [I,C]; A61K0031-351 [I,A]; A61K0031-403 [I,C];
A61K0031-405 [I,A]; A61K0031-455 [I,C]; A61K0031-455 [I,A];
A61K0031-47 [I,C]; A61K0031-47 [I,A]; A61K0031-505 [I,C];
A61K0031-505 [I,A]; A61P0003-00 [I,C]; A61P0003-04 [I,A];
A61P0003-10 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L29 ANSWER 4 OF 6 USPATFULL on STN

Full Text

AN 2007:155230 USPATFULL

TI Compounds and Methods of Treating Insulin Resistance and Cardiomyopathy

IN Nestor, John, 725 Lynwood Drive, Encinitas, CA, UNITED STATES 92024

PA FORBES MEDI-TECH (RESEARCH), INC., Seattle, WA, UNITED STATES, 98101
(U.S. corporation)

PI US 20070135450 A1 20070614

AI US 2006-618120 A1 20061229 (11)

RLI Continuation of Ser. No. US 2005-248491, filed on 12 Oct 2005, GRANTED,
Pat. No. US 7189748

PRAI US 2004-617911P 20041012 (60)
US 2005-664835P 20050323 (60)
US 2005-664919P 20050323 (60)
US 2005-693463P 20050623 (60)

DT Utility

FS APPLICATION

LN.CNT 1513

INCL INCLM: 514/256.000
INCLS: 514/357.000; 514/374.000; 514/534.000; 514/400.000; 514/365.000;
514/367.000; 514/378.000; 514/375.000; 546/336.000; 544/242.000;
548/152.000; 548/205.000; 548/217.000; 548/235.000; 548/335.500;
562/452.000

NCL NCLM: 514/256.000
NCLS: 514/357.000; 514/365.000; 514/367.000; 514/374.000; 514/375.000;
514/378.000; 514/400.000; 514/534.000; 544/242.000; 546/336.000;
548/152.000; 548/205.000; 548/217.000; 548/235.000; 548/335.500;
562/452.000

IC IPCI A61K0031-505 [I,A]; A61K0031-44 [I,A]; A61K0031-428 [I,A];
A61K0031-426 [I,A]; A61K0031-421 [I,A]; A61K0031-4172 [I,A];
A61K0031-4164 [I,C*]; A61K0031-195 [I,A]; A61K0031-185 [I,C*]
IPCR A61K0031-505 [I,C]; A61K0031-505 [I,A]; A61K0031-185 [I,C];
A61K0031-195 [I,A]; A61K0031-4164 [I,C]; A61K0031-4172 [I,A];
A61K0031-421 [I,C]; A61K0031-421 [I,A]; A61K0031-426 [I,C];
A61K0031-426 [I,A]; A61K0031-428 [I,C]; A61K0031-428 [I,A];
A61K0031-44 [I,C]; A61K0031-44 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L29 ANSWER 5 OF 6 USPATFULL on STN

Full Text

AN 2006:93411 USPATFULL

TI Compounds and methods for treating insulin resistance and cardiomyopathy

IN Nestor, John, Encinitas, CA, UNITED STATES

PA Therapei Pharmaceuticals, Inc., San Diego, CA, UNITED STATES (U.S.
corporation)

PI US 20060079542 A1 20060413
US 7189748 B2 20070313

AI US 2005-248491 A1 20051012 (11)

PRAI US 2004-617911P 20041012 (60)
US 2005-664835P 20050323 (60)
US 2005-664919P 20050323 (60)
US 2005-693463P 20050623 (60)

DT Utility

FS APPLICATION

LN.CNT 1522
INCL INCLM: 514/269.000
INCLS: 514/365.000; 514/357.000; 514/374.000; 514/367.000; 514/378.000;
514/397.000; 514/400.000; 514/375.000; 514/567.000; 544/309.000;
546/335.000; 548/204.000; 548/236.000; 548/248.000; 548/335.500;
562/452.000
NCL NCLM: 514/364.000; 514/269.000
NCLS: 514/400.000; 548/136.000; 548/340.100; 514/357.000; 514/365.000;
514/367.000; 514/374.000; 514/375.000; 514/378.000; 514/397.000;
514/567.000; 544/309.000; 546/335.000; 548/204.000; 548/236.000;
548/248.000; 548/335.500; 562/452.000
IC IPCI A61K0031-513 [I,A]; A61K0031-44 [I,A]; A61K0031-426 [I,A];
A61K0031-421 [I,A]; A61K0031-42 [I,A]
IPCI-2 A61K0031-41 [I,A]; A61K0031-4164 [I,A]; C07D0233-56 [I,A];
C07D0233-00 [I,C*]; C07D0271-10 [I,A]; C07D0271-00 [I,C*]
IPCR A61K0031-41 [I,C]; A61K0031-41 [I,A]; A61K0031-4164 [I,C];
A61K0031-4164 [I,A]; C07D0233-00 [I,C]; C07D0233-56 [I,A];
C07D0271-00 [I,C]; C07D0271-10 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L29 ANSWER 6 OF 6 USPATFULL on STN

Full Text

AN 2002:343928 USPATFULL
TI Method for measuring serine palmitoyltransferase in mammalian tissue and
use thereof
IN Carton, Jill M., Malvern, PA, UNITED STATES
D'Andrea, Michael R., Cherry Hill, NJ, UNITED STATES
Uhlinger, David J., Flemington, NJ, UNITED STATES
PI US 20020197654 A1 20021226
AI US 2002-100861 A1 20020319 (10)
PRAI US 2001-277252P 20010320 (60)
DT Utility
FS APPLICATION
LN.CNT 1687
INCL INCLM: 435/007.210
INCLS: 424/009.600
NCL NCLM: 435/007.210
NCLS: 424/009.600
IC [7]
ICM G01N033-567
IPCI G01N033-567 [ICM, 7]
IPCR C07K0016-40 [I,C*]; C07K0016-40 [I,A]; C12N0009-10 [I,C*];
C12N0009-10 [I,A]; C12Q0001-48 [I,C*]; C12Q0001-48 [I,A];
G01N033-50 [I,C*]; G01N033-50 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 16:42:46 ON 30 JUN 2008)

FILE 'REGISTRY' ENTERED AT 16:42:58 ON 30 JUN 2008
E MYRIOCIN/CN

L1 1 S E3

FILE 'DRUGU' ENTERED AT 16:44:06 ON 30 JUN 2008
L2 3 S L1

FILE 'MEDLINE' ENTERED AT 16:44:36 ON 30 JUN 2008
L3 79 S L1
L4 102 S MYRIOCIN
L5 132 S L3 OR L4
L6 2979 S (SERINE PALMITOYLTRANSFERASE INHIBIT? OR SPT?)
L7 56663 S ATHEROSCLEROSIS
L8 6 S L5 AND L7
L9 5 S L6 AND L7

FILE 'CA' ENTERED AT 16:47:26 ON 30 JUN 2008
L10 126 S L1
L11 183 S MYRIOCIN/AB,BI
L12 208 S L10 OR L11
L13 2680 S (SERINE PALMITOYLTRANSFERASE INHIBIT? OR SPT?)/AB,BI

L14 58627 S ATHEROSCLEROSIS/AB,BI
L15 9 S L12 AND L14
L16 14 S L13 AND L14

FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 16:51:14 ON 30 JUN 2008
L17 13 S L1
L18 72 S MYRIOCIN
L19 9 S MYRIOCIN/CLM
L20 7642 S (SERINE PALMITOYLTRANSFERASE INHIBIT? OR SPT?)
L21 981 S (SERINE PALMITOYLTRANSFERASE INHIBIT? OR SPT?)/CLM
L22 42005 S ATHEROSCLEROSIS
L23 7443 S ATHEROSCLEROSIS/CLM
L24 74 S L17 OR L18
L25 18 S L22 AND L24
L26 6 S L17 AND L19
L27 1 S L23 AND L26
L28 373 S L20 AND L22
L29 6 S L21 AND L23

=> d 126 106

6 ANSWERS ARE AVAILABLE. SPECIFIED ANSWER NUMBER EXCEEDS ANSWER SET SIZE
The answer numbers requested are not in the answer set.
ENTER ANSWER NUMBER OR RANGE (1):end

=> d 126 1-6

L26 ANSWER 1 OF 6 USPATFULL on STN

Full Text

AN 2008:93774 USPATFULL
TI CEREBROSPINAL FLUID SHUNT HAVING LONG TERM ANTI-OCCLUSION AGENT DELIVERY
IN Trescony, Paul V., Champlin, MN, UNITED STATES
Koullick, Edouard, Golden Valley, MN, UNITED STATES
PA Medtronic, Inc., Minneapolis, MN, UNITED STATES (U.S. corporation)
PI US 20080082036 A1 20080403
AI US 2006-380157 A1 20060425 (11)
DT Utility
FS APPLICATION
LN.CNT 745
INCL INCLM: 604 8
INCLS: 604/034.000
NCL NCLM: 604/008.000
NCLS: 604/034.000
IC IPCI A61F0002-20 [I,A]; A61M0001-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L26 ANSWER 2 OF 6 USPATFULL on STN

Full Text

AN 2008:30792 USPATFULL
TI Imidazole-Based Hmg-Coa Reductase Inhibitors
IN Homan, Reynold, Ann Arbor, MI, UNITED STATES
Karathanasis, Sotirios K., Carmel, IN, UNITED STATES
Panek, Robert L., Ann Arbor, MI, UNITED STATES
Park, Tae-Sik, Ann Arbor, MI, UNITED STATES
Rekhter, Mark D., Carmel, IN, UNITED STATES
PA Warner-Lambert Company, LLC (U.S. corporation)
PI US 20080027088 A1 20080131
AI US 2005-594348 A1 20050321 (10)
WO 2005-IB733 20050321
20070815 PCT 371 date
PRAI US 2004-557021P 20040326 (60)
DT Utility
FS APPLICATION
LN.CNT 1702
INCL INCLM: 514/275.000
INCLS: 514/311.000; 514/356.000; 514/415.000; 514/460.000; 514/560.000;
514/789.000
NCL NCLM: 514/275.000
NCLS: 514/311.000; 514/356.000; 514/415.000; 514/460.000; 514/560.000;
514/789.000
IC IPCI A61K0031-201 [I,A]; A61K0031-185 [I,C*]; A61K0031-351 [I,A];
A61K0031-405 [I,A]; A61K0031-403 [I,C*]; A61K0031-455 [I,A];
A61K0031-47 [I,A]; A61K0031-505 [I,A]; A61P0003-04 [I,A];

IPC R A61P0003-10 [I,A]; A61P0003-00 [I,C*];
A61K0031-185 [I,C]; A61K0031-201 [I,A]; A61K0031-21 [I,C*];
A61K0031-22 [I,A]; A61K0031-345 [I,C*]; A61K0031-345 [I,A];
A61K0031-351 [I,C]; A61K0031-351 [I,A]; A61K0031-403 [I,C];
A61K0031-405 [I,A]; A61K0031-455 [I,C]; A61K0031-455 [I,A];
A61K0031-47 [I,C]; A61K0031-47 [I,A]; A61K0031-505 [I,C];
A61K0031-505 [I,A]; A61P0003-00 [I,C]; A61P0003-04 [I,A];
A61P0003-10 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L26 ANSWER 3 OF 6 USPATFULL on STN

Full Text

AN 2007:224176 USPATFULL
TI ORAL DELIVERY OF THERAPEUTIC AGENTS USING TIGHT JUNCTION AGONISTS
IN Eddington, Natalie D., School of Pharmacy, UMB, Dept. of Pharma. Sci.,
20 Penn Street, HSF II 543, Baltimore, MD, UNITED STATES 21201
Fasano, Alessio, 3128 River Valley Chase, West Friendship, MD, UNITED
STATES 21794
Song, Keon-Hyoung, 3113 West Springs Drive, Apt. F, Ellicott City, MD,
UNITED STATES 21043
PA UNIVERSITY OF MARYLAND, BALTIMORE, Baltimore, MD, UNITED STATES, 21201
(U.S. corporation)
PI US 20070196272 A1 20070823
AI US 2007-673192 A1 20070209 (11)
PRAI US 2006-771453P 20060209 (60)
DT Utility
FS APPLICATION
LN.CNT 1321
INCL INCLM: 424/001.110
INCLS: 514/014.000; 514/015.000; 514/016.000; 514/017.000; 514/008.000;
514/012.000; 514/003.000; 514/011.000; 514/171.000; 514/056.000;
514/044.000; 424/094.630; 514/018.000
NCL NCLM: 424/001.110
NCLS: 424/094.630; 514/003.000; 514/008.000; 514/011.000; 514/012.000;
514/014.000; 514/015.000; 514/016.000; 514/017.000; 514/018.000;
514/044.000; 514/056.000; 514/171.000
IC IPCI A61K0051-00 [I,A]; A61K0038-28 [I,A]; A61K0038-14 [I,A];
A61K0038-22 [I,A]; A61K0031-727 [I,A]; A61K0031-726 [I,C*];
A61K0038-48 [I,A]; A61K0038-43 [I,C*]; A61K0031-56 [I,A];
A61M0036-14 [I,A]; A61M0036-00 [I,C*]
IPC R A61K0051-00 [I,C]; A61K0051-00 [I,A]; A61K0031-56 [I,C];
A61K0031-56 [I,A]; A61K0031-726 [I,C]; A61K0031-727 [I,A];
A61K0038-14 [I,C]; A61K0038-14 [I,A]; A61K0038-22 [I,C];
A61K0038-22 [I,A]; A61K0038-28 [I,C]; A61K0038-28 [I,A];
A61K0038-43 [I,C]; A61K0038-48 [I,A]; A61M0036-00 [I,C];
A61M0036-14 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L26 ANSWER 4 OF 6 USPATFULL on STN

Full Text

AN 2006:314702 USPATFULL
TI Antibiotic kit and composition and uses thereof
IN Friedman, Doron, Karmei Yosef, ISRAEL
Besonov, Alex, Rehovot, ISRAEL
Tamarinkin, Dov, Maccabim, ISRAEL
Eini, Meir, Ness Ziona, ISRAEL
PA Foamix Ltd., Rehovot, ISRAEL (non-U.S. corporation)
PI US 20060269485 A1 20061130
AI US 2006-448490 A1 20060607 (11)
RLI Continuation-in-part of Ser. No. US 2004-911367, filed on 4 Aug 2004,
PENDING Continuation-in-part of Ser. No. US 2005-532618, filed on 22 Dec
2005, PENDING A 371 of International Ser. No. WO 2003-IB5527, filed on
24 Oct 2003
PRAI US 2003-492385P 20030804 (60)
US 2002-429546P 20021129 (60)
US 2005-688244P 20050607 (60)
DT Utility
FS APPLICATION
LN.CNT 2938
INCL INCLM: 424/045.000
NCL NCLM: 424/045.000
IC IPCI A61L0009-04 [I,A]

IPCR A61L0009-04 [I,C]; A61L0009-04 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L26 ANSWER 5 OF 6 USPATFULL on STN

Full Text

AN 2005:209536 USPATFULL
TI Ceramide de novo synthesis-based therapeutic and prophylactic methods, and related articles of manufacture
IN Worgall, Tilla S., New York, NY, UNITED STATES
Deckelbaum, Richard J., Hastings-on-Hudson, NY, UNITED STATES
PI US 20050182020 A1 20050818
AI US 2003-712684 A1 20031114 (10)
DT Utility
FS APPLICATION
LN.CNT 1544
INCL INCLM: 514/054.000
INCLS: 514/560.000; 514/475.000; 514/651.000; 514/733.000
NCL NCLM: 514/054.000
NCLS: 514/475.000; 514/560.000; 514/651.000; 514/733.000
IC [7]
ICM A61K031-739
ICS A61K031-336; A61K031-202; A61K031-138; A61K031-05
IPCI A61K031-739 [ICM, 7]; A61K031-336 [ICS, 7]; A61K031-202 [ICS, 7];
A61K031-185 [ICS, 7, C*]; A61K031-138 [ICS, 7]; A61K031-05
[ICS, 7]; A61K031-045 [ICS, 7, C*]
IPCR A61K031-00 [I,C*]; A61K031-00 [I,A]; A61K031-045 [I,C*];
A61K031-05 [I,A]; A61K031-138 [I,C*]; A61K031-138 [I,A];
A61K031-185 [I,C*]; A61K031-202 [I,A]; A61K031-336 [I,C*];
A61K031-336 [I,A]; A61K031-739 [I,C*]; A61K031-739 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L26 ANSWER 6 OF 6 USPATFULL on STN

Full Text

AN 75:70458 USPATFULL
TI Myriocin and process of preparation
IN Kluepfel, Dieter, Montreal, Canada
Kudelski, Alicia, Westmount, Canada
Bagli, Jehan, Kirkland, Canada
PA Ayerst Mckenna and Harrison Ltd., Montreal, Canada (non-U.S.
corporation)
PI US 3928572 19751223
AI US 1971-114445 19710211 (5)
DT Utility
FS Granted
LN.CNT 310
INCL INCLM: 424/122.000
INCLS: 195/081.000
NCL NCLM: 424/122.000
NCLS: 435/128.000; 435/911.000
IC [2]
ICM H61K035-00
IPCI H61K035-00 [ICM, 2]
IPCR A61K031-185 [I,C*]; A61K031-195 [I,A]
EXF 424/122; 195/81
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> kwic 6

KWIC IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d 126 kwic 6

L26 ANSWER 6 OF 6 USPATFULL on STN

CLM What is claimed is:

1. **Myriocin**, a compound which a. is effective in inhibiting the growth of pathogenic fungi; b. is soluble in methanol, somewhat less. . .

CLM What is claimed is:

2. **Myriocin**, of claim 1 which is trans-2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxo-6-eicosenoic acid having the structural

formula ##SPC2##

CLM What is claimed is:
3. A process for the production of **myriocin**, trans-2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxo-6-eicosenoic acid which comprises culturing a suspension of spores of Myriococcum albomyces NRRL 3858 in an aqueous nutrient medium containing. . . and a temperature of about 40° to 55°C until substantial anti-fungal activity is imparted to the medium by production of **myriocin**, and recovering **myriocin** from the culture medium.

CLM What is claimed is:
. . . out by filtering the fermentation mixture, extracting the mycelial growth with a lower alkanol, evaporating said extract and purifying crude **myriocin** thus obtained by crystallization.

IT 35891-70-4P
(manuf. of, with Myriococcum albomyces)

=> log y			
COST IN U.S. DOLLARS	SINCE FILE	TOTAL	
	ENTRY	SESSION	
FULL ESTIMATED COST	28.71	102.10	
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL	
	ENTRY	SESSION	
CA SUBSCRIBER PRICE	0.00	-1.50	

STN INTERNATIONAL LOGOFF AT 16:57:22 ON 30 JUN 2008